Oddo BHF upgraded Pharma Mar to Outperform from Neutral with a EUR 48 price target. The company’s lung cancer drug Zepzelca has a lot of potential and the stock’s current low valuation creates a buying opportunity, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly